Joanne Lager

1.9k total citations
37 papers, 1.2k citations indexed

About

Joanne Lager is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joanne Lager has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 16 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joanne Lager's work include PI3K/AKT/mTOR signaling in cancer (12 papers), Cancer Treatment and Pharmacology (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Joanne Lager is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (12 papers), Cancer Treatment and Pharmacology (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Joanne Lager collaborates with scholars based in United States, France and United Kingdom. Joanne Lager's co-authors include Jeffrey P. Hodge, Danny Rischin, Michael Friedländer, Mark Messing, Bo Ma, Kenneth C. Hancock, A. Benjamin Suttle, Thangam Arumugham, Mohammed M. Dar and Nicolaas Schaap and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Joanne Lager

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joanne Lager United States 17 563 439 389 389 296 37 1.2k
Paola Aimone Switzerland 17 372 0.7× 549 1.3× 229 0.6× 338 0.9× 235 0.8× 43 1.1k
Nushmia Z. Khokhar United States 15 479 0.9× 898 2.0× 95 0.2× 569 1.5× 478 1.6× 29 1.4k
Yasuyuki Hirashima Japan 26 557 1.0× 542 1.2× 123 0.3× 184 0.5× 100 0.3× 81 1.8k
Véronique D’Hondt France 21 298 0.5× 781 1.8× 99 0.3× 335 0.9× 163 0.6× 83 1.3k
Jens Ersbøll Denmark 15 276 0.5× 381 0.9× 282 0.7× 188 0.5× 371 1.3× 29 1.1k
Francesco Turturro United States 19 580 1.0× 637 1.5× 253 0.7× 159 0.4× 412 1.4× 64 1.4k
J J Costanzi United States 20 295 0.5× 641 1.5× 158 0.4× 283 0.7× 187 0.6× 36 1.2k
Clémentine Sarkozy France 20 263 0.5× 791 1.8× 371 1.0× 95 0.2× 108 0.4× 73 1.4k
Hyeon‐Seok Eom South Korea 24 412 0.7× 864 2.0× 301 0.8× 95 0.2× 530 1.8× 133 1.7k
He Huang China 19 537 1.0× 480 1.1× 55 0.1× 159 0.4× 76 0.3× 78 1.4k

Countries citing papers authored by Joanne Lager

Since Specialization
Citations

This map shows the geographic impact of Joanne Lager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne Lager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne Lager more than expected).

Fields of papers citing papers by Joanne Lager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne Lager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne Lager. The network helps show where Joanne Lager may publish in the future.

Co-authorship network of co-authors of Joanne Lager

This figure shows the co-authorship network connecting the top 25 collaborators of Joanne Lager. A scholar is included among the top collaborators of Joanne Lager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne Lager. Joanne Lager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jonasch, Eric, Bradley A. McGregor, Pavlos Msaouel, et al.. (2024). 1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study. Annals of Oncology. 35. S1011–S1012. 4 indexed citations
2.
Mehnert, Janice M., Gerald M. Edelman, Mark N. Stein, et al.. (2017). A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors. Investigational New Drugs. 36(1). 36–44. 11 indexed citations
3.
Wheler, Jennifer J., David G. Mutch, Joanne Lager, et al.. (2017). Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. The Oncologist. 22(4). 377–e37. 25 indexed citations
4.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2017). Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. The Lancet Haematology. 4(7). e317–e324. 222 indexed citations
5.
Abramson, Vandana G., Jeffrey G. Supko, Tarah J. Ballinger, et al.. (2016). Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clinical Cancer Research. 23(14). 3520–3528. 23 indexed citations
6.
Brown, Jennifer R., Matthew S. Davids, Jordi Rodón, et al.. (2015). Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clinical Cancer Research. 21(14). 3160–3169. 45 indexed citations
7.
Wen, Patrick Y., Antonio Omuro, Manmeet S. Ahluwalia, et al.. (2015). Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology. 17(9). 1275–1283. 69 indexed citations
8.
Sidhu, Sukhvinder, Coumaran Égile, Jianguo Ma, et al.. (2013). Abstract 4638: Anti-tumor activity of pimasertib in combination with SAR245409 or SAR245408 in human primary colorectal cancer xenograft models bearing PI3K/KRas and KRas mutations.. Cancer Research. 73(8_Supplement). 4638–4638. 2 indexed citations
9.
10.
Brown, Jennifer R., Matthew S. Davids, Jordi Rodón, et al.. (2011). Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. Blood. 118(21). 2683–2683. 10 indexed citations
11.
Papadopoulos, Kyriakos P., Pau Abrisqueta, Amita Patnaik, et al.. (2011). A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma. Blood. 118(21). 1608–1608. 11 indexed citations
12.
Heath, Elisabeth I., E. Gabriela Chiorean, Christopher J. Sweeney, et al.. (2010). A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 88(6). 818–823. 85 indexed citations
13.
Bullock, Karen, William P. Petros, Islam R. Younis, et al.. (2010). A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemotherapy and Pharmacology. 67(2). 465–474. 25 indexed citations
14.
15.
Friedländer, Michael, Kenneth C. Hancock, Danny Rischin, et al.. (2010). A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology. 119(1). 32–37. 171 indexed citations
16.
Frentzas, Sophia, Morris D. Groves, Jorge Barriuso, et al.. (2009). Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. Journal of Clinical Oncology. 27(15_suppl). 2040–2040. 9 indexed citations
17.
Lager, Joanne, Elizabeth Lyden, James R. Anderson, et al.. (2006). Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of Clinical Oncology. 24(21). 3415–3422. 56 indexed citations
18.
Zafar, S. Yousuf, Johanna C. Bendell, Joanne Lager, et al.. (2006). Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3097–3097. 28 indexed citations
19.
Kurtzberg, Joanne, T J Ernst, Michael J. Keating, et al.. (2005). Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies. Journal of Clinical Oncology. 23(15). 3396–3403. 129 indexed citations
20.
Tirado, Carlos A, et al.. (2004). A case of infantile acute lymphoblastic leukemia presenting with rearrangement of MLL at 11q23 and apparent insertion or translocation at 10p12. Cancer Genetics and Cytogenetics. 154(1). 57–59. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Aimone Breakdown of academic impact, for papers by Nushmia Z. Khokhar Breakdown of academic impact, for papers by Yasuyuki Hirashima Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Jens Ersbøll Breakdown of academic impact, for papers by Francesco Turturro Breakdown of academic impact, for papers by J J Costanzi Breakdown of academic impact, for papers by Clémentine Sarkozy Breakdown of academic impact, for papers by Hyeon‐Seok Eom Breakdown of academic impact, for papers by He Huang
Rankless by CCL
2026